Recently, a large‐scale multiomics study12 has shown that the difference between HER2 IHC 1+ and IHC 2+ breast cancer in the hormone receptor‐negative subgroup was more significant than in the hormone receptor‐positive subgroup at the levels of the transcriptome, proteome, and metabolome. This evidence concerns the gene NR4A1 and breast carcinoma.